Watchlist Price Alert

Milestone Pharmaceuticals... (MIST)

NASDAQ: MIST · Real-Time Price · USD

1.79

0.03 (1.70%)

At close: Jun 24, 2025, 3:59 PM

1.77

-1.43%

After-hours: Jun 24, 2025, 07:35 PM EDT

1.70% (1D)

Bid	1.72
Market Cap	95.97M
Revenue (ttm)	n/a
Net Income (ttm)	-31.16M
EPS (ttm)	-0.77
PE Ratio (ttm)	-2.33
Forward PE	-2.05
Analyst	Buy

Ask	1.81
Volume	507,917
Avg. Volume (20D)	2,078,258
Open	1.78
Previous Close	1.76
Day's Range	1.75 - 1.82
52-Week Range	0.63 - 2.75
Beta	0.92

About MIST

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MIST

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MIST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

-60.89%

Milestone Pharmaceuticals shares are trading lower... Unlock content with Pro Subscription

10 months ago

+2.86%

Milestone Pharmaceuticals shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $9 price target.

News

1 month ago · zacks.com

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

Milestone Pharmaceuticals (MIST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · seekingalpha.com

Stock Picks From Seeking Alpha's March 2025 New Analysts

In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT...

2 months ago · zacks.com

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst

Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues.

2 months ago · reuters.com

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' nasal spray to treat a type of heart condition, the company said on Friday.